证券代码：300314 证券简称：戴维医疗 公告编号：2024-020 宁波戴维医疗器械股份有限公司 关于股东续签一致行动协议书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"或"戴维医 疗"）于2024年5月7日收到股东陈云勤、陈再宏、陈再慰的通知，鉴 于股东陈云勤、陈再宏、陈再慰等3人于2021年5月7日签署的《一致行 动协议书》即将到期，于2024年5月7日续签了《一致行动协议书》， 继续作为一致行动人，具体情况如下： 一、协议书签署的背景情况 1、公司股东陈云勤，持有公司60,820,000股，占公司全部已发行 股份总数的21.12%；股东陈再宏，持有公司71,108,200股，占公司全 部已发行股份总数的24.69%；股东陈再慰，持有公司58,320,000股， 占公司全部已发行股份总数的20.25%。 2、陈云勤、陈再宏、陈再慰等3人于2021年5月7日签署了《一致 行动协议书》，对一致行动关系和有效期等进行了明确约定，该协议 有效期至2024年5月8日届满，原一致行动人于2024年5月7日续签 ...

Investment Rating - The report maintains a "Buy" rating for the company [3][5]. Core Insights - The company's main products have shown steady growth, with the minimally invasive surgery business experiencing significant growth [1]. - Continuous investment in research and development is strengthening the company's core competitiveness [2]. - The establishment of overseas subsidiaries is expanding the company's international market coverage [3]. Financial Performance Summary - In 2023, the company achieved revenue of 618.30 million yuan, a year-on-year increase of 22.18%, and a net profit attributable to the parent company of 147.61 million yuan, up 51.62% [11]. - The company expects revenues of 780.11 million yuan, 981.38 million yuan, and 1,223.73 million yuan for 2024, 2025, and 2026 respectively, with net profits of 200.50 million yuan, 250.99 million yuan, and 328.47 million yuan for the same years [3][4]. - The gross profit margin for 2023 was 58.20%, remaining stable year-on-year [12]. Growth Drivers - The increase in sales is attributed to the implementation of national financial subsidy loan policies, which significantly boosted sales [11]. - The obstetric care equipment business generated revenue of 358 million yuan, a 20.17% increase, due to the introduction of new high-end products and optimization of product structure [11]. - The minimally invasive surgical instruments business saw revenue of 245 million yuan, a 24.48% increase, driven by the release of collective procurement [11]. International Expansion - In 2023, overseas revenue reached 208 million yuan, a year-on-year increase of 25.93%, with the establishment of a subsidiary in Portugal to serve as a base for overseas research, production, and sales [12]. - The company has provided technical and product services to over 140 countries and regions globally [12].

Financial Performance - Total operating revenue for Q1 2024 was CNY 155,328,964.53, a decrease of 1.94% compared to CNY 157,862,759.12 in the same period last year[21] - The company's net profit for Q1 2024 was CNY 38,107,228.76, down from CNY 50,019,287.49 in the same period last year, representing a decrease of approximately 23.9%[49] - Operating profit for the first quarter was CNY 44,488,936.73, compared to CNY 57,880,407.58 in Q1 2023, reflecting a decline of about 23.0%[49] - Net profit attributable to shareholders of the listed company is ¥38,107,228.76, down 23.81% from ¥50,019,287.49 in the previous year[29] - The company reported a total comprehensive income of ¥38,107,228.76 for the current period, compared to ¥50,019,287.49 in the previous year[24] Cash Flow and Assets - The net cash flow from operating activities is -¥10,331,039.53, a decline of 249.65% compared to ¥6,903,274.52 in the same period last year[29] - Cash and cash equivalents at the end of the period are ¥443,087,497.54, down from ¥409,457,239.69 at the end of the previous year[25] - The company's cash and cash equivalents decreased from CNY 571,365,961.98 to CNY 456,258,061.24, a decline of approximately 20.1%[39] - Total assets at the end of the reporting period amount to ¥1,364,964,670.42, a decrease of 0.66% from ¥1,374,082,918.93 at the end of the previous year[29] - The total assets of Ningbo David Medical Instruments Co., Ltd. amounted to CNY 1,364,964,670.42, a slight decrease from CNY 1,374,082,918.93[39] Liabilities and Equity - The total liabilities decreased from CNY 210,610,507.00 at the beginning of the period to CNY 163,520,520.34 at the end of the period, reflecting a reduction of approximately 22.34%[21] - The total equity attributable to shareholders increased from CNY 1,163,472,411.93 to CNY 1,201,444,150.08, representing a growth of about 3.26%[21] - Shareholders' equity attributable to the listed company is ¥1,201,444,150.08, an increase of 3.26% from ¥1,163,472,411.93[29] - The accounts payable decreased from CNY 119,209,647.28 to CNY 99,484,516.41, a reduction of approximately 16.6%[39] Expenses and Investments - Research and development expenses increased to CNY 10,287,345.11 from CNY 8,627,320.97, marking a rise of approximately 19.2%[49] - The total operating costs for the quarter were CNY 108,971,100.08, slightly down from CNY 110,973,756.29, indicating a decrease of about 1.8%[49] - Financial expenses increased by 1072.24% to -¥2,740,443.68 due to reduced exchange loss from currency fluctuations[32] - Investment income decreased by 138.73% to -¥2,554,623.67 mainly due to reduced investment income accounted for using the equity method[32] Receivables and Prepayments - Accounts receivable increased by 99.35% to ¥47,493,541.24 due to increased credit limits granted to distributors[32] - Prepayments rose by 92.35% to ¥26,205,071.44 primarily due to increased prepayments for raw materials and outsourced R&D[32] - The accounts receivable increased significantly to CNY 47,493,541.24 from CNY 23,824,645.62, representing an increase of about 99.5%[39] Government Support and Transparency - The company received government subsidies amounting to CNY 1,084,655.18 during the quarter, contributing positively to the financial results[10] - The company maintains a commitment to transparency, ensuring that all financial disclosures are accurate and complete[6] - The company has not classified any non-recurring gains or losses as regular operating income, ensuring clarity in financial reporting[12]

证券代码：300314 证券简称：戴维医疗 公告编号：2024-017 上述变更文件与"浙械注准 20152020235"、"浙械注准 20152020236"、 "浙械注准 20152020237"、"浙械注准 20152020238"、"浙械注准 20162021053"、"浙械注准 20172020239"、"浙械注准 20192020471" 医疗器械注册证共同使用。 二、对公司的影响及风险提示 上述医疗器械注册证"生产地址"的变更，对公司发展具有积极影响， 但尚无法预测上述变更事宜对公司未来营业收入的影响，敬请广大投资者 予以关注并注意投资风险。 宁波戴维医疗器械股份有限公司 关于全资子公司医疗器械注册证变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司宁 波维尔凯迪医疗器械有限公司于近日取得7项由浙江省药品监督管理局颁 发的《中华人民共和国医疗器械变更注册（备案）文件》，具体情况如下： | 序号 | 产品名称 | 注册证编号 | 注册分类 | 变更内容 | | --- | --- ...

线 开源证券 戴维医疗（300314.SZ） 2024 年 04 月 10 日 股价走势图 公 司 研 究 投资评级：买入（维持） -100% -50% 0% 50% 2023-04 2023-08 2023-12 戴维医疗 沪深300 相关研究报告 | --- | --- | |---------------------------|---------------------------| | | | | 余汝意（分析师） | 司乐致（分析师） | | yuruyi@kysec.cn | silezhi@kysec.cn | | 证书编号： S0790523070002 | 证书编号： S0790523110003 | 吻合器腔镜化与电动化已是大势，集采政策有望提高电吻渗透率和国产化率 联盟、山东、湖南、京津冀 3+N 联盟集采已全面到来。 公司 2018 年取得国内第一张电动腔镜吻合器注册证，目前已有 5 张注册证，其中 2 张Ⅲ类，Ⅲ类证在手术适用范围上更优，可闭合离断血管。公司并推出全球首款 智能全自动转弯吻合器，进一步抬高电动吻合器赛道护城河。同时公司有望借联 盟和省级集采之力加快准入，快速提高医院 ...

Financial Performance - The company's operating revenue for 2023 reached ¥618,298,238, representing a 22.18% increase compared to ¥506,036,692 in 2022[23]. - Net profit attributable to shareholders for 2023 was ¥147,610,911, a significant increase of 51.62% from ¥97,577,629 in 2022[23]. - The basic earnings per share for 2023 was ¥0.51, reflecting a 50.00% increase from ¥0.34 in 2022[23]. - The total assets at the end of 2023 amounted to ¥1,374,082,918, marking a 9.69% increase from ¥1,252,694,543 at the end of 2022[23]. - The net cash flow from operating activities for 2023 was ¥135,198,386, which is a 21.18% increase compared to ¥111,569,973 in 2022[23]. - Operating profit reached 171.36 million yuan, reflecting a year-on-year growth of 52.99%[60]. - The net profit excluding non-recurring gains and losses was 128.52 million yuan, reflecting a growth of 61.78% from the previous year[94]. - The company achieved a total operating revenue of 618.30 million yuan, representing a year-on-year growth of 22.18%[94]. - The gross profit margin for the medical device manufacturing sector was 58.42%, with a slight decrease of 0.21% compared to the previous year[113]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 1.80 RMB per 10 shares to all shareholders, based on a total of 288 million shares[3]. - The company has a total of 288 million shares outstanding, which is the basis for the proposed profit distribution plan[3]. - The total shareholding of 24.73 million shares held by directors and supervisors as of the end of the reporting period[191]. Research and Development - The company invested 48.06 million yuan in R&D, which is 7.77% of total revenue, supporting innovation and development[72]. - The company holds a total of 233 patents, including 53 invention patents, 133 utility model patents, and 47 design patents, providing a strong technical foundation for sustainable development[72]. - The company has increased its R&D personnel to 156 in 2023, a rise of 12.23% from 139 in 2022, with the proportion of R&D staff remaining stable at 17.99%[126]. - R&D investment amounted to ¥48,059,212.59 in 2023, representing 7.77% of operating revenue, down from 9.06% in 2022[126]. - The company is actively involved in the research and development of minimally invasive surgical instruments, aligning its products with advanced technologies in the industry[91]. Market Expansion and Product Development - The company plans to continue expanding its market presence and investing in new product development[23]. - The company is actively expanding its product line into minimally invasive surgical instruments and emergency ICU products, with several related products currently under development[59]. - The company is focusing on high-value consumables in the large surgical market, continuously improving its product structure and technology[66]. - The company is developing new medical devices, including a neonatal jaundice treatment device and a disposable laparoscopic closure device, currently under review[134]. - The company plans to expand its product offerings in the neonatal care segment, targeting both domestic and international markets[128]. Government Policies and Industry Trends - National policies have been implemented to support the medical device industry, enhancing innovation and progress, including guidelines for minimally invasive surgeries in tertiary hospitals[35]. - The "14th Five-Year" plan emphasizes the importance of centralized procurement to lower drug and medical consumable prices, alleviating the financial burden on the public[37]. - The implementation of the three-child policy is expected to stimulate demand in the medical device sector, promoting industry growth[39]. - The demand for medical devices is expected to rise due to increasing disposable income, an aging population, and enhanced insurance coverage, positioning the industry for significant growth opportunities[49]. Competitive Landscape - The medical device industry is characterized by high barriers to entry, low volatility, and increasing concentration, indicating a strong potential for market consolidation[48]. - The company faces intensified competition in the medical device industry, with international giants maintaining strong market shares, particularly in tertiary hospitals[172]. - The company is increasing R&D efforts to enhance product technology and develop differentiated products to improve brand recognition and market position[172]. Corporate Governance and Management - The company has a board of 9 directors, including 3 independent directors, ensuring compliance and diversity in decision-making[184]. - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, finance, institutions, and business operations[187]. - The company adheres to strict information disclosure principles, ensuring transparency and timely communication with investors[185]. - The management team has a strong commitment to corporate governance and compliance with industry standards[194]. Financial Health and Cash Flow - Operating cash inflow totaled CNY 693,450,206.88, an increase of 20.59% compared to CNY 575,028,400.61 in 2022[136]. - Cash and cash equivalents increased by CNY 167,580,111.24, representing a 205.33% rise from CNY 54,885,576.63 in 2022[136]. - The company reported a significant increase in the net cash flow from investment activities due to higher recoveries of investments compared to the previous year[136]. Challenges and Risks - The declining birth rate in China is leading to reduced demand for infant care equipment, directly impacting the company's business performance in this segment[175]. - Fluctuations in raw material prices significantly impact the company's operating costs and gross margins, posing risks to profitability[177]. - Centralized procurement policies for high-value medical consumables may lead to price reductions for the company's products, affecting gross margins and profitability[176].

宁波戴维医疗器械股份有限公司 董事会秘书工作细则 宁波戴维医疗器械股份有限公司 董事会秘书工作细则 宁波戴维医疗器械股份有限公司 董事会秘书工作细则 宁波戴维医疗器械股份有限公司 董事会秘书工作细则 第一章 总 则 第一条 为规范宁波戴维医疗器械股份有限公司（以下简称"公司"）的公 司行为，明确董事会秘书的职责权限，根据《中华人民共和国公司法》（以下简 称《公司法》）、《上市公司治理准则》《深圳证券交易所创业板股票上市规则》（以 下简称《上市规则》）和《宁波戴维医疗器械股份有限公司章程》（以下简称《公 司章程》）的规定，制定本细则。 第二条 董事会秘书为公司的高级管理人员，对公司和董事会负责。有关法 律、法规和规范性文件以及《公司章程》等对公司高级管理人员的有关规定，适 用于董事会秘书。 （二）被中国证监会采取不得担任上市公司董事、监事、高级管理人员的市 场禁入措施，期限尚未届满； （三）被证券交易场所公开认定为不适合担任上市公司董事、监事和高级管 理人员，期限尚未届满； 1 宁波戴维医疗器械股份有限公司 董事会秘书工作细则 （四）最近三十六个月受到中国证监会行政处罚； 董事会秘书是公司与深圳证券交易所（以下 ...

根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求(以下简称"企业内部控制规范体系")，结合宁波戴维医疗器械股份有限公司 （以下简称"公司"）内部控制制度和评价办法，在内部控制日常监督和专项监 督的基础上，对公司截止2023年12月31日(内部控制评价报告基准日)的内部控制 有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经营管理层负责组织领导企业内部控制的日常运行。 公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚 假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担 个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化 可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部 控制评价结果推测未来内部控制的 ...

宁波戴维医疗器械股份有限公司 委托理财管理制度 宁波戴维医疗器械股份有限公司 委托理财管理制度 宁波戴维医疗器械股份有限公司 委托理财管理制度 第一章 总则 第一条 为加强与规范宁波戴维医疗器械股份有限公司（以下简 称"公司"） 委托理财业务的管理，提高资金运作效率，保证公司 资金、财产安全，有效防范、控制委托理财决策和执行过程中的风险， 提高投资收益，维护公司及股东利益，依据《中华人民共和国证券法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司 自律监管指引第2号——创业板上市公司规范运作》《深圳证券交易 所上市公司自律监管指引第7号——交易与关联交易》及《公司章程》 等法律、法规、规范性文件的有关规定，结合公司的实际情况，特制 定本制度。 第二条 本制度所称委托理财是指在国家政策及深圳证券交易 所创业板相关业务规则允许的情况下，公司或控股子公司在控制投资 风险并履行投资决策程序的前提下，以提高资金使用效率、增加现金 资产收益为原则，对闲置资金通过商业银行理财、信托理财及其他理 财工具进行运作和管理，在确保安全性、流动性的基础上实现资金保 值增值的行为。 以募集资金进行委托理财的，应遵守国家 ...

宁波戴维医疗器械股份有限公司 章程 宁波戴维医疗器械股份有限公司 章 程 1 宁波戴维医疗器械股份有限公司 章程 目 录 第三章 股份 第四章 股东和股东大会 第五章 董事会 第七章 监事会 第八章 财务会计制度、利润分配和审计 第九章 通知与公告 第十章 合并、分立、增资、减资、解散和清算 第十一章 修改章程 第十二章 附则 2 第一章 总则 第二章 经营宗旨和范围 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第一节 股东 第二节 股东大会的一般规定 第三节 股东大会的召集 第四节 股东大会的提案与通知 第五节 股东大会的召开 第六节 股东大会的表决和决议 第一节 董事 第二节 董事会 第六章 经理及其他高级管理人员 第一节 监事 第二节 监事会 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第一节 通知 第二节 公告 第一节 合并、分立、增资和减资 第二节 解散和清算 宁波戴维医疗器械股份有限公司 章程 第一章 总则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行 为，根据《中华人民共和国公司法》(以下简称《公司法》)、《中华人民共 和国证券法》（以下 ...